Stockscreener 앱 받기
34.42
2.75%
0.92
전일 마감가:
$33.50
열려 있는:
$33.83
하루 거래량:
5.16M
Relative Volume:
1.43
시가총액:
$3.87B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-37.01
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+7.53%
1개월 성능:
+27.06%
6개월 성능:
-0.23%
1년 성능:
-46.78%
1일 변동 폭
$33.53
$35.22
1주일 범위
$31.22
$35.22
52주 변동 폭
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.42 | 3.77B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics Inc. Stock Analysis and ForecastUnmatched market gains - PrintWeekIndia
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - MSN
Is Viking Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - MSN
Viking Therapeutics Q2: Confidently Continuing The Recovery (NASDAQ:VKTX) - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Opus Genetics (IRD) - The Globe and Mail
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives - TipRanks
What drives Viking Therapeutics Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Viking Therapeutics stock maintains Buy rating at Stifel on obesity drug potential - Investing.com Australia
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Viking Therapeutics EPS miss sends shares down 7% - MSN
Viking Therapeutics Surges to 433rd in Trading Volume as Strategic Partnership and Clinical Success Fuel Stock Rally - AInvest
Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity - insights.citeline.com
Viking Therapeutics (VKTX) Stock Rating Maintained by Raymond James | VKTX Stock News - GuruFocus
Viking Therapeutics Q2 Earnings Miss Estimates, R&D Expenses Rise - AInvest
Viking Therapeutics stock rating reiterated by Cantor Fitzgerald at $104 - Investing.com Canada
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Insider Monkey
Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program - MSN
H.C. Wainwright reiterates Buy rating on Viking Therapeutic stock at $102 - Investing.com Nigeria
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ... - Yahoo Finance
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: - GuruFocus
Viking Therapeutics Advances Clinical Pipeline Amid Financial Losses - TipRanks
Viking Therapeutics' Q2 2025 Earnings Call: Unpacking Key Contradictions in Phase III Study Strategy - AInvest
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
What analysts say about Viking Therapeutics Inc. stockSuperior stock selection - jammulinksnews.com
Viking Therapeutics EPS miss sends shares down 7% (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates - Benzinga
Viking Therapeutics (VKTX) Reports Q2 Loss, Misses EPS Expectati - GuruFocus
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics shares fall as Q2 loss exceeds estimates By Investing.com - Investing.com India
Viking (VKTX) Q2 2025 Earnings Call Transcript - Mitrade
Viking Therapeutics reports Q2 EPS (58c), consensus (44c) - TipRanks
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | VKTX Stock News - GuruFocus
Viking Therapeutics Advances Dual Obesity Drug Strategy: Injectable Phase 3 Trials Begin as Oral Version Nears Data - Stock Titan
Viking Therapeutics (VKTX) Options Activity Surges Ahead of Earnings | VKTX Stock News - GuruFocus
Viking Therapeutics to Report Q2 2025 Financial Results on July 23, 2025 - AInvest
Viking Therapeutics, Inc. (NASDAQ:VKTX) institutional owners may be pleased with recent gains after 38% loss over the past year - Yahoo Finance
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 - Finansavisen
Viking Therapeutics (VKTX) Set to Release Q2 Earnings Results - GuruFocus
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Mitrade
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
0.97%
0.22%
자본화:
|
볼륨(24시간):